ClinicalTrials.gg
RecruitingNCT07522684Updated Apr 20, 2026

Polynucleotide + Hyaluronic Acid Gel With Xenogeneic Graft for Intrabony Periodontal Defects

An interventional study of Polynucleotide and hyaluronic acid-based gel and Control in Periodontitis, sponsored by University of Sao Paulo. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by University of Sao Paulo · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Periodontitis by University of Sao Paulo — 3 open to participants now, 4 under way, none of them phase 3. Periodontitis · University of Sao Paulo.

Planned enrollment
3rd of 12
66 · median 46
Started
2026
with 2 others
No phase
6 of 13
3 open now
Registered
9th of 13
by date

Among the 13 studies in Periodontitis by University of Sao Paulo, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 with no phase, and was the 9th registered.

Periodontitis

1,242 studies on the registry are indexed under Periodontitis; 304 are open to participants now.

Browse Periodontitis studies →

Open to participants now

3 of the 13 studies in Periodontitis by University of Sao Paulo are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 163 Periodontitis studies recruiting now, 80 (49%) set no upper age limit and 62 (38%) stop at 75 or younger; 12 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Periodontitis by University of Sao Paulo, or all of them as a file.
02

Study summary

Over the last 30 years, the prevalence of periodontitis (PE) has increased substantially, including among younger populations, highlighting the need to improve the management of this condition as a chronic disease and to develop techniques that favor its control and stability in the short and long term. After non-surgical periodontal therapy (NSPT), the first phase of PE treatment, residual periodontal pockets may persist, often associated with intraosseous defects, which compromise the tooth's prognosis and are associated with disease progression and increased treatment complexity. Surgical treatment of intrabony defects often results in the formation of long junctional epithelium, weakly attached to the root surface, since true regeneration of periodontal tissues is an unpredictable event and depends on complex biological processes. In recent decades, various biomaterials have been proposed as aids to open-flap debridement (OFD) in the surgical treatment of intrabony defects, with the aim of promoting periodontal regeneration, enhancing clinical results and favoring treatment prognosis. Recently, the combination of polynucleotides (PN) and hyaluronic acid (HA) has emerged as a promising auxiliary strategy to promote periodontal regeneration, due to its biological potential in stimulating cell growth and increasing cell viability. The aim of this controlled, randomized, parallel-group clinical study is to compare OFD alone with its association with xenogenous bone graft or xenogenous bone graft plus gel containing PN/HA in the surgical treatment of intrabony defects in patients with PE (stages III or IV, grades B or C). The patients will be randomly divided into three experimental groups (n=22): control (C), xenogeneic bone graft (XENO) and xenogeneic bone graft plus gel containing PN/HA (R-XENO). The patients will receive NSPT, and after eight weeks will undergo surgical procedures to treat the intrabony defects (baseline). Clinical, radiographic, tomographic and immunological periodontal parameters will be assessed at baseline and after 12 months. The wound healing index will be recorded 1, 2 and 6 weeks after the surgical procedure. Patient-centered outcomes will be assessed by means of a visual analog scale (VAS), applied two weeks after the surgical procedure, and oral health-related quality of life (OHRQoL) questionnaires, applied at the beginning of the study and after 6 and 12 months. At the start of the study and after 6 and 12 months, anthropometric data will be collected, blood pressure (BP) will be measured and questionnaires will be applied to survey socio-demographic and nutritional parameters. The data obtained will be statistically analyzed (p\<0.05).

Read the detailed description

This controlled, randomized, parallel-group clinical study aims to compare open-flap debridement alone with its association with xenogeneic bone graft or xenogeneic bone graft plus gel containing polynucleotides (PN) and hyaluronic acid (HA) in the surgical treatment of intrabony defects in patients with periodontitis (stages III or IV, grades B or C), based on clinical, immunologic, radiographic/tomographic parameters and patient-centered outcomes.

The sample size was calculated using the primary variable clinical attachment level (CAL), considering a mean difference of 1 mm between the experimental groups as the minimum value and a standard deviation of 0.91. Considering β = 80% and α = 5%, the required sample size was 18 patients for each experimental group, with each patient contributing a single defect. Considering a dropout of 20%, the number was increased to 22 patients per experimental group, making a total of 66 patients.

Patients who meet the inclusion criteria will be randomly assigned to one of three experimental groups (n=22) in a 1:1 allocation ratio: Group C (Control), including intrabony defects treated with open flap debridement alone; Group XENO, including open flap debridement associated with xenogeneic bone grafting; and Group R-XENO, including open flap debridement associated with xenogeneic bone grafting and a PN/HA-containing gel. Randomization will be performed using software, which will identify each participant by a numerical code. Group allocation will be carried out on the day of surgery by the study coordinator.

Surgical treatment: After local anesthesia using an infiltration or nerve block technique with a sterile injectable solution of 2% mepivacaine hydrochloride (20 mg/mL) and 1:100,000 epinephrine (10 µg/mL), intrasulcular incisions will be made on the buccal and lingual/palatal aspects using a 15C surgical blade (Stainless Steel Surgical Blades, Swann-Morton®, Sheffield, England), extending one tooth mesially and one tooth distally to the tooth associated with the defect. A full-thickness flap will be carefully elevated on the buccal and lingual/palatal sides to expose 2 to 3 mm of the alveolar crest. Meticulous debridement of the defect will be performed, along with the removal of subgingival biofilm and calculus using ultrasonic combined with manual instruments, followed by irrigation with sterile saline solution. The defects will be filled as follows: with blood clot only in the group C; with xenogeneic bone graft (Geistlich Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) in the XENO group; and with xenogeneic bone graft (Geistlich Bio-Oss®) plus PN/HA-containing gel (REGENFAST®, Geistlich Pharma AG, Wolhusen, Switzerland) in the R-XENO group. Primary soft tissue closure was achieved by interrupted mattress suture technique with non-resorbable monofilament polyamide 5-0 sutures (Soft Blue®, Techsuture, Bauru, SP, Brazil).

Outcome assessment will be conducted at predefined time points. The primary outcome is clinical attachment level (CAL). Secondary outcomes include probing depth (PD); radiographic and tomographic measures of bone fill and defect resolution; quantitative analysis of biomarkers related to tissue neoformation (PDGF-BB, VEGF, BMP-2); early wound healing assessed by standardized indices; and patient-reported outcomes, including pain perception and oral health-related quality of life.

03

Conditions studied

  • Periodontitis

Browse trials for

Keywords

  • Clinical Trial
  • Periodontitis
  • Wound Healing
  • Polynucleotides
  • Hyaluronic Acid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years of age;
  • diagnosis of periodontitis stage III or IV, grade B or C (Chapple et al., 2018; Papapanou et al., 2018);
  • full-mouth plaque score (FMPS) and full-mouth bleeding score (FMBS) of ≤ 20%;
  • presence of a 2- or 3-wall intrabony defect with a depth ≥ 3 mm and probing depth and clinical attachment level ≥ 5 mm in the interproximal region of a single- or multi-rooted tooth;
  • pulp vitality or satisfactory endodontic treatment in the tooth to be treated;
  • at least 1 mm of keratinized tissue on the buccal surface of the tooth to be treated.

Exclusion criteria

Exclusion Criteria:

  • presence of furcation involvement associated with the intrabony defect;
  • presence of systemic conditions that may affect the progression of periodontitis or the response to its treatment;
  • long-term use of anti-inflammatory or medications;
  • use of antimicrobials within the last 6 months;
  • continuous use of mouthwashes containing antimicrobial agents within the last 6 months;
  • need for prophylactic antibiotic therapy for routine dental procedures;
  • current or past tobacco use within the last 5 years;
  • pregnancy;
  • breastfeeding.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Active comparator
    Control

    Intrabony defects treated with open flap debridement alone

    Other: Control

  • Active comparator
    XENO

    Intrabony defects treated with open flap debridement associated with xenogeneic bone grafting

    Device: Xenogeneic bone graft

  • Experimental
    R-XENO

    Intrabony defects treated with open flap debridement associated with polynucleotide and hyaluronic acid-based gel plus xenogeneic bone grafting

    Device: Polynucleotide and hyaluronic acid-based gel

Interventions

  • DevicePolynucleotide and hyaluronic acid-based gel

    The polynucleotide and hyaluronic acid-based gel will be applied in combination with a xenogeneic bone graft to fill the intrabony defects.

  • OtherControl

    Intrabony defects treated with open flap debridement alone

  • DeviceXenogeneic bone graft

    The xenogeneic bone graft will be applied to fill the intrabony defects.

06

What researchers measure

Primary outcomes

  1. Clinical Attachment Level (CAL)

    Distance between the cemento-enamel junction and the bottom of the periodontal pocket/sulcus, in milimeters

    Time frame: Baseline and 12 months

Secondary outcomes

  1. Probing depth (PD)

    Distance between the gingival margin and the bottom of the periodontal pocket/sulcus, in milimeters

    Time frame: Baseline and 12 months

  2. Changes in the alveolar bone crest

    Distance between the cemento-enamel junction and the alveolar crest in milimeters, assessed radiographically

    Time frame: Baseline and 12 months

  3. Radiographic defect depth

    Distance between the alveolar crest and the defect base in milimeters, assessed radiographically

    Time frame: Baseline and 12 months

  4. Vertical bone loss

    Distante between the cemento-enamel junction and the defect base in milimeters, assessed radiographically

    Time frame: Baseline and 12 months

  5. Tomographic vertical bone loss

    Distance, in milimeters, between the cemento-enamel junction and the defect base in coronal sections of computed tomography

    Time frame: Baseline and 12 months

  6. Buccolingual width of the defect

    Buccolingual width, in milimeters, assessed in axial sections of computed tomography

    Time frame: Baseline and 12 months

  7. Platelet-derived growth factor (PDGF)-BB

    Quantification in pg/mL using a multiplex assay with Milliplex plates (Millipore)

    Time frame: Baseline and 12 months

  8. Vascular endothelial growth factor (VEGF)

    Quantification in pg/mL using a multiplex assay with Milliplex plates (Millipore)

    Time frame: Baseline and 12 months

  9. Bone morphogenetic protein (BMP)-2

    Quantification in pg/mL using an enzyme-linked immunosorbent assay (ELISA).

    Time frame: Baseline and 12 months

  10. Wound Healing Index (WHI).

    A score from 1 to 3 will be assigned according to the following criteria: i) score 1 - uneventful healing, i.e., no gingival edema, erythema, suppuration, patient discomfort, or flap dehiscence; ii) score 2 - uneventful healing with slight gingival edema, erythema, patient discomfort, or flap dehiscence, but no suppuration; iii) score 3 - poor wound healing, with significant gingival edema, erythema, patient discomfort, flap dehiscence, or any suppuration.

    Time frame: 1, 2 and 6 weeks

  11. Visual Analogue Scale

    Patients will complete a questionnaire using a 100 mm visual analogue scale (VAS) , where 0 means no pain/hardship and 100 means unbearable pain/hardship

    Time frame: 2 weeks

  12. Oral Health Impact Profile (OHIP-14) questionnaire

    Oral health-related quality of life assessed using the 14-item Oral Health Impact Profile (OHIP-14) questionnaire. Each item is scored on a 5-point Likert scale ranging from 0 (never) to 4 (very often). The total score is calculated as the sum of all item responses, ranging from 0 to 56, with higher scores indicating worse oral health-related quality of life.

    Time frame: Baseline, 6 and 12 months

  13. Oral Health Related Quality of Life (OHRQoL-UK) questionnaire

    Oral health-related quality of life assessed using the Oral Health-Related Quality of Life-UK (OHRQoL-UK) questionnaire. The instrument consists of 16 items covering physical, psychological, and social dimensions. Each item is scored on a 5-point scale ranging from 1 (very bad effect) to 5 (very good effect). The total score is calculated as the sum of all item responses, ranging from 16 to 80, with higher scores indicating better oral health-related quality of life.

    Time frame: Baseline, 6 and 12 months

07

Study locations

1 of 1 sites recruiting
  • Ribeirão Preto School of Dentistry, University of São Paulo
    Ribeirão Preto, São Paulo 14040904, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available from the investigator upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for May 2028, 27 months after the start.

Of 484 non-industry interventional studies with no phase under Periodontitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 31. This study's planned 27 months is above that.

Counting every sponsor, half of 498 studies reached it within 15 months; a quarter within 8 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Apr 13, 2026
StartActual
Feb 25, 2026
Primary completionEst.
May 2028
CompletionEst.
May 2028
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07522684
Collaborators
Geistlich Pharma AG
Responsible party
Flávia Aparecida Chaves Furlaneto (Professor, University of Sao Paulo) — Principal investigator
First posted
Apr 13, 2026
Start date
Feb 25, 2026
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Apr 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion